/

Società

4M

Non verificato

4Moving Biotech

Di cosa scriviamo

BiotecnologiaFarmaceuticaFitnessIndustriaSalute

4 comunicati stampa

Guarda tutti i comunicati

08/01/2026

4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics

Fonte

4Moving Biotech

Emittente

1.00

0

16/07/2025

Scienza

Sanità

Farmaceutica

Fitness

Medicina - Varie

Biotecnologia

Salute

Industria

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis

Fonte

4Moving Biotech

Emittente

1.00

0

27/03/2025

Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis

Fonte

4Moving Biotech

Emittente

1.00

0

02/07/2024

4Moving Biotech welcomes Luc Boblet as Chief Executive Officer to lead next phase of growth

Fonte

4Moving Biotech

Emittente

1.00

0

Seguaci

0

Compatibilità

0